Table 19.
Diagnostic performance of VCTE in autoimmune liver disease
| Disease | Reference | No. of patients | Nation | Significant fibrosis (≥F2) |
Advanced fibrosis (≥F3) |
Cirrhosis (F4) |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of patients (%) | AUC (95% CI) | Cutoff value (kPa) | Sensitivity%/specificity% | No. of patients (%) | AUC (95% CI) | Cutoff value (kPa) | Sensitivity%/specificity% | No. of patients (%) | AUC (95% CI) | Cutoff value (kPa) | Sensitivity%/specificity% | ||||
| PBC | Gómez-Dominguez et al. [330] (2008) | 55 | Spain | - | - | - | - | 16 (29.1) | 0.86 (0.72–0.94) | 14.7 | 56.0/100.0 | 2 (3.6) | 0.96 (0.87–0.99) | 15.6 | 88.0/98.0 |
| Floreani et al. [333] (2011) | 120 | Italia | 88 (80.0) | 0.89 (0.81–0.97) | 5.9 | 82.0/92.0 | 50 (50.0) | 0.92 (0.85–0.99) | 7.6 | 90.0/92.0 | 17 (15.0) | 0.99 (0.94–1.00) | 11.4 | 99.0/94.0 | |
| Corpechot et al. [331] (2012) | 103 | France | 52 (50.0) | 0.91 (0.86–0.96) | 8.8 | 67.0/100.0 | 30 (29.0) | 0.95 (0.92–0.99) | 10.7 | 90.0/93.0 | 15 (14.5) | 0.99 (0.97–1.00) | 16.9 | 93.0/99.0 | |
| Koizumi et al. [332] (2017) | 44 | Japan | 17 (38.6) | 0.92 (0.80–0.97) | 16.0 | 94.1/80.8 | 13 (29.5) | 0.91 (0.79–0.97) | 17.9 | 92.3/76.7 | 6 (13.6) | 0.91 (0.69–0.98) | 25.1 | 83.3/70.7 | |
| AIH | Hartl et al. [343] (2016) | 94 | Germany | 56 (59.6) | 0.87 | 5.8 | 90.0/72.0 | 33 (35.1) | 0.93 | 10.4 | 83.0/98.0 | 20 (13.8) | 0.96 | 16.0 | 88.0/100.0 |
| Anastasiou et l. [341] (2016) | 53 | Germany | 44 (83.0) | 0.78 | 10.05 | 61.4/88.9 | 29 (54.7) | 0.74 | 12.1 | 83.3/80.9 | 15 (28.3) | 0.842 | 19.0 | 81.8/92.9 | |
| Xu et al. [339] (2017) | 100 | China | 84 (84.0) | 0.88 (0.79–0.97) | 6.45 | 82.1/87.5 | 50 (50.0) | 0.88 (0.82–0.95) | 8.75 | 80.0/84.0 | 23 (23.0) | 0.91 (0.85–0.98) | 12.5 | 87.0/89.6 | |
| Guo et al. [344] (2017) | 108 | China | 78 (72.2) | 0.89 (0.82–0.95) | 6.27 | 84.6/76.7 | 54 (50.0) | 0.90 (0.84–0.96) | 8.18 | 79.6/85.2 | 24 (22.2) | 0.88 (0.77–0.98) | 12.67 | 87.5/88.1 | |
| Paranaguá-Vezozzo et al. [345] (2023) | 33 | Brazil | 26 (78.8) | 0.91 (0.81–1.00) | 6.3 | 76.9/100.0 | 18 (54.5) | 0.83 (0.69–0.98) | 8.7 | 72.2/80.0 | 8 (24.2) | 0.88 (0.76–1.00) | 12.3 | 87.5/88.0 | |
| PSC | Corpechot et al. [348] (2014) | 66 | France | 32 (48.5) | 0.84 | 7.4 | 60.0/86.0 | 15 (22.7) | 0.93 | 9.6 | 93.3/83.0 | 9 (13.6) | 0.95 | 14.4 | 100.0/88.0 |
| Ehlken et al. [349] (2016) | 62 | Germany | 27 (43.5) | 0.91 (0.82–0.99) | 8.8 | 81.5/88.6 | 20 (32.3) | 0.95 (0.89–1.00) | 9.6 | 90.0/90.5 | 16 (25.8) | 0,98 (0.93–1.00) | 14.4 | 68.8/97.8 | |
| Muir et al. [325] (2019) | 58 | US | - | - | - | - | - | 0.80 (0.68–0.91) | 9.6 | 67.0/74.0 | - | 0.95 (0.88–1.00) | 14.4 | 100.0/83.0 | |
VCTE, vibration-controlled transient elastography; PBC, primary biliary cholangitis; AIH, autoimmune hepatitis; PSC, primary sclerosing cholangitis; AUC, area under the curve; CI, confidence interval; kPa, kilopascal.